Mantle cell lymphoma—Update on molecular biology, prognostication and treatment approaches
Hematological Oncology · 2023-06 · 41 (S1) · 36-42
DOI: 10.1002/hon.3149 ↗At a glance
Übersichtsarbeit in Hematological Oncology, published online on 2023-06-09. Written by Elisabeth Silkenstedt and 1 co-authors. Institution: Department of Medicine III, LMU University Hospital, Munich, Germany. Major MEDLINE topics: Lymphoma, Mantle-Cell. Cited 67 times so far (Crossref); 41 references. The full text is freely available (open access, CC BY-NC 4.0).
Abstract (original language)
Mantle cell lymphoma (MCL) is clinically characterized by its heterogenous behavior with courses ranging from indolent cases that do not require therapy for years to highly aggressive MCL with very limited prognosis. The development and implementation of new targeted and immunotherapeutic approaches have already improved therapeutic options especially for refractory or relapsed disease. Nevertheless, to further optimize MCL treatment, early identification of individual risk profile and risk‐adapted, patient‐tailored choice of therapeutic strategy needs to be prospectively incorporated in clinical patient management. This review summarizes the current knowledge and standard of care regarding biology and clinical management of MCL, highlighting the implementation of new therapeutic approaches especially targeting the immune system.
Subjects
MeSH terms (MEDLINE)
Author keywords
Authors and institutions
- Department of Medicine III, LMU University Hospital, Munich, Germany.
Cite
APA
Silkenstedt, E., & Dreyling, M. (2023). Mantle cell lymphoma—Update on molecular biology, prognostication and treatment approaches. Hematological Oncology, 41(S1), 36-42. https://doi.org/10.1002/hon.3149
Vancouver
Silkenstedt E, Dreyling M. Mantle cell lymphoma—Update on molecular biology, prognostication and treatment approaches. Hematological Oncology. 2023;41(S1):36-42. doi:10.1002/hon.3149
BibTeX
@article{Silkenstedt2023,
author = {Silkenstedt, Elisabeth and Dreyling, Martin},
title = {Mantle cell lymphoma—Update on molecular biology, prognostication and treatment approaches},
journal = {Hematological Oncology},
year = {2023},
volume = {41},
number = {S1},
pages = {36--42},
doi = {10.1002/hon.3149}
}
EUVIMED